camel milk and diabetes

Effect of camel milk on glycemic control and lipid profile of diabetic patients treated with long-acting insulin

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201310094794N10

Enrollment

Registered

2016-03-02

Start date

2015-08-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insulin-dependent diabetes. Insulin-dependent diabetes mellitus

Interventions

Intervention 1: Intervention group: camel milk, 500 ml/day, 3 month. Intervention 2: Control group: cow milk, 500 ml/day, 3 month.

Treatment - Other

Placebo

Intervention group: camel milk, 500 ml/day, 3 month

Control group: cow milk, 500 ml/day, 3 month

Eligibility

Sex/Gender

All

Age

30 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Patients with diabetes treated with glargine; age range: 30 to 70 years old. Exclusion Criteria:pregnancy or lactation; smoking and alcohol consumption; Lactose intolerance; having cardiovascular disease, liver, lung, kidney and Chronic gastrointestinal and thyroid dysfunction; following from the weight loss diets two months prior to study; weight changes (increase or decrease) more than 5 kg two months prior to study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Fasting blood glucose. Timepoint: Baseline and after 3 months. Method of measurement: Biochemical analysis.;HA1C. Timepoint: Baseline and after 3 months. Method of measurement: Biochemical analysis.;Lipid profile: total cholesterol, Triglyceride, HDL, LDL. Timepoint: Baseline and after 3 months. Method of measurement: Biochemical analysis.;Blood insuline. Timepoint: Baseline and after 3 months. Method of measurement: Biochemical analysis.;Injectable insuline dose. Timepoint: Baseline and after 3 months. Method of measurement: Questionnaire.	—

Measure

Time frame

Fasting blood glucose. Timepoint: Baseline and after 3 months. Method of measurement: Biochemical analysis.;HA1C. Timepoint: Baseline and after 3 months. Method of measurement: Biochemical analysis.;Lipid profile: total cholesterol, Triglyceride, HDL, LDL. Timepoint: Baseline and after 3 months. Method of measurement: Biochemical analysis.;Blood insuline. Timepoint: Baseline and after 3 months. Method of measurement: Biochemical analysis.;Injectable insuline dose. Timepoint: Baseline and after 3 months. Method of measurement: Questionnaire.

—

Secondary

Measure	Time frame
Dietary Factors. Timepoint: Baseline and after 3 month. Method of measurement: 24h dietary recall.;Body mass index. Timepoint: Baseline and after 3 months. Method of measurement: Anthropometric measurements.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFereidoun Azizi

Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences

azizi@endocrine.ac.ir+98 21 2243 2500

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026